TARGETED THERAPIES Afatinib-new therapy option for EGFR-mutant lung cancer

被引：85

作者：

Yu, Helena A. ^{[1
]}

Pao, William ^{[2
]}

机构：

[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv,Div Solid Tumor Oncol, New York, NY 10065 USA

[2] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN 37212 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2013年 / 10卷 / 10期

关键词：

1ST-LINE TREATMENT; OPEN-LABEL; ERLOTINIB; CHEMOTHERAPY; MULTICENTER; PHASE-3; TRIAL;

D O I：

10.1038/nrclinonc.2013.154

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients.

引用

页码：551 / 552

页数：2

共 10 条

[1]

[Anonymous], ANN ONCOL SUPPL 9

[2]

Katakami N., J CLIN ONCOL

[3] Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial [J].

Miller, Vincent A. ;

Hirsh, Vera ;

Cadranel, Jacques ;

Chen, Yuh-Min ;

Park, Keunchil ;

Kim, Sang-We ;

Zhou, Caicun ;

Su, Wu-Chou ;

Wang, Mengzhao ;

Sun, Yan ;

Heo, Dae Seog ;

Crino, Lucio ;

Tan, Eng-Huat ;

Chao, Tsu-Yi ;

Shahidi, Mehdi ;

Cong, Xiuyu Julie ;

Lorence, Robert M. ;

Yang, James Chih-Hsin .

LANCET ONCOLOGY, 2012, 13 (05) :528-538

[4] Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer [J].

Pao, William ;

Chmielecki, Juliann .

NATURE REVIEWS CANCER, 2010, 10 (11) :760-774

[5] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].

Rosell, Rafael ;

Carcereny, Enric ;

Gervais, Radj ;

Vergnenegre, Alain ;

Massuti, Bartomeu ;

Felip, Enriqueta ;

Palmero, Ramon ;

Garcia-Gomez, Ramon ;

Pallares, Cinta ;

Miguel Sanchez, Jose ;

Porta, Rut ;

Cobo, Manuel ;

Garrido, Pilar ;

Longo, Flavia ;

Moran, Teresa ;

Insa, Amelia ;

De Marinis, Filippo ;

Corre, Romain ;

Bover, Isabel ;

Illiano, Alfonso ;

Dansin, Eric ;

de Castro, Javier ;

Milella, Michele ;

Reguart, Noemi ;

Altavilla, Giuseppe ;

Jimenez, Ulpiano ;

Provencio, Mariano ;

Angel Moreno, Miguel ;

Terrasa, Josefa ;

Munoz-Langa, Jose ;

Valdivia, Javier ;

Isla, Dolores ;

Domine, Manuel ;

Molinier, Olivier ;

Mazieres, Julien ;

Baize, Nathalie ;

Garcia-Campelo, Rosario ;

Robinet, Gilles ;

Rodriguez-Abreu, Delvys ;

Lopez-Vivanco, Guillermo ;

Gebbia, Vittorio ;

Ferrera-Delgado, Lioba ;

Bombaron, Pierre ;

Bernabe, Reyes ;

Bearz, Alessandra ;

Artal, Angel ;

Cortesi, Enrico ;

Rolfo, Christian ;

Sanchez-Ronco, Maria ;

Drozdowskyj, Ana .

LANCET ONCOLOGY, 2012, 13 (03) :239-246

[6]

Sequist LV, 2013, J CLIN ONCOL

[7] Erlotinib in previously treated non-small-cell lung cancer [J].

Shepherd, FA ;

Pereira, JR ;

Ciuleanu, T ;

Tan, EH ;

Hirsh, V ;

Thongprasert, S ;

Campos, D ;

Maoleekoonpiroj, S ;

Smylie, M ;

Martins, R ;

van Kooten, M ;

Dediu, M ;

Findlay, B ;

Tu, DS ;

Johnston, D ;

Bezjak, A ;

Clark, G ;

Santabárbara, P ;

Seymour, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :123-132

[8]

Yang JC, J CLIN ONCOL

[9] Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers [J].

Yu, Helena A. ;

Arcila, Maria E. ;

Rekhtman, Natasha ;

Sima, Camelia S. ;

Zakowski, Maureen F. ;

Pao, William ;

Kris, Mark G. ;

Miller, Vincent A. ;

Ladanyi, Marc ;

Riely, Gregory J. .

CLINICAL CANCER RESEARCH, 2013, 19 (08) :2240-2247

[10] Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study [J].

Zhou, Caicun ;

Wu, Yi-Long ;

Chen, Gongyan ;

Feng, Jifeng ;

Liu, Xiao-Qing ;

Wang, Changli ;

Zhang, Shucai ;

Wang, Jie ;

Zhou, Songwen ;

Ren, Shengxiang ;

Lu, Shun ;

Zhang, Li ;

Hu, Chengping ;

Hu, Chunhong ;

Luo, Yi ;

Chen, Lei ;

Ye, Ming ;

Huang, Jianan ;

Zhi, Xiuyi ;

Zhang, Yiping ;

Xiu, Qingyu ;

Ma, Jun ;

Zhang, Li ;

You, Changxuan .

LANCET ONCOLOGY, 2011, 12 (08) :735-742

← 1 →